Immunome Inc
Follow $IMNM
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $IMNM by emailVeridion Score
BETAMEDIUM CONF · 5 of 6 factors measuredsnapshot unavailable for IMNM. Cause unavailable.
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is IMNM moving today?
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
IMNM overview
Related filings and maps
Congress activity in IMNM
No receipt-qualified filings found.
IMNM contract awards, year to date.
Public federal awards linked to this ticker.
IMNM lobbying filings, year to date.
Registered lobbying filings matched to Immunome Inc.